Maintenance of long-term lung allograft health in lung transplant recipients (LTRs) requires a fine balancing act between providing sufficient immunosuppression to reduce the risk of rejection whilst at the same time not over-immunosuppressing individuals and exposing them to the myriad of immunosuppressant drug side-effects that can cause morbidity and mortality. At present, lung transplant physicians only have limited and rather blunt tools available to assist them with this task. Although therapeutic drug monitoring provides clinically useful information about single time point and longitudinal exposure of LTRs to immunosuppressants, it lacks precision in determining the functional level of immunosuppression that an individual is experiencing. There is a significant gap in our ability to monitor lung allograft health and therefore tailor optimal personalised immunosuppression regimens. Molecular diagnostics performed on blood, bronchoalveolar lavage or lung tissue that can detect early signs of subclinical allograft injury, differentiate rejection from infection or distinguish cellular from humoral rejection could offer clinicians powerful tools in protecting lung allograft health. In this review, we look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use. Although donor-derived cell-free DNA and tissue transcriptomics appear to be the techniques with the most immediate clinical potential, more robust data are required on their performance and additional clinical value beyond standard of care.

Department of Respiratory Diseases Hôpital Marie Lannelongue Groupe Hospitalier Paris Saint Joseph and Paris Saclay University Paris France

Institute of Transplantation Newcastle Upon Tyne Hospitals NHS Trust Newcastle Upon Tyne UK

Newcastle University Translational and Clinical Research Institute Newcastle upon Tyne UK

Prague Lung Transplant Program Department of Pneumology Motol University Hospital and 2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

The lungs at the frontlines of immunity. Nat Immunol 2015; 16: 17. doi:10.1038/ni.3069 PubMed DOI

Graham CN, Watson C, Barlev A, et al. . Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ 2022; 25: 230–237. doi:10.1080/13696998.2022.2033050 PubMed DOI

van der Mark SC, Hoek RAS, Hellemons ME. Developments in lung transplantation over the past decade. Eur Respir Rev 2020; 29: 190132. doi:10.1183/16000617.0132-2019 PubMed DOI PMC

Meyer KC, Raghu G, Verleden GM, et al. . An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J 2014; 44: 1479–1503. doi:10.1183/09031936.00107514 PubMed DOI

Verleden GM, Glanville AR, Lease ED, et al. . Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment–a consensus report from the pulmonary council of the ISHLT. J Heart Lung Transplant 2019; 38: 493–503. doi:10.1016/j.healun.2019.03.009 PubMed DOI

Bos S, Vos R, Van Raemdonck DE, et al. . Survival in adult lung transplantation: where are we in 2020? Curr Opin Organ Transplant 2020; 25: 268–273. doi:10.1097/MOT.0000000000000753 PubMed DOI

Martinu T, Koutsokera A, Benden C, et al. . ISHLT consensus on standardization of bronchoalveolar lavage in lung transplantation. J Heart Lung Transplant 2019; 38: S120–S121. doi:10.1016/j.healun.2019.01.283 PubMed DOI PMC

Stewart S, Fishbein MC, Snell GI, et al. . Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229–1242. doi:10.1016/j.healun.2007.10.017 PubMed DOI

Tosi D, Carrinola R, Morlacchi LC, et al. . Surveillance transbronchial biopsy program to evaluate acute rejection after lung transplantation: a single institution experience. Transplant Proc 2019; 51: 198–201. doi:10.1016/j.transproceed.2018.04.073 PubMed DOI

Bhorade S, Husain A, Liao C, et al. . Interobserver variability in grading transbronchial lung biopsy specimens after lung transplantation. Chest 2013; 143: 1717–1724. doi:10.1378/chest.12-2107 PubMed DOI

Berry G, Burke M, Andersen C, et al. . Pathology of pulmonary antibody-mediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 2013; 32: 14–21. doi:10.1016/j.healun.2012.11.005 PubMed DOI

Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. . Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant 2016; 16: 1216–1228. doi:10.1111/ajt.13589 PubMed DOI

Levine DJ, Glanville AR, Aboyoun C, et al. . Antibody-mediated rejection of the lung: a consensus report of the international society for heart and lung transplantation. J Heart Lung Transplant 2016; 35: 397–406. doi:10.1016/j.healun.2016.01.1223 PubMed DOI

Rosenheck JP, Keller BC, Fehringer G, et al. . Why cell-free DNA can be a “game changer” for lung allograft monitoring for rejection and infection. Curr Pulmonol Rep 2022; 11: 75–85. doi:10.1007/s13665-022-00292-8 PubMed DOI PMC

Kustanovich A, Schwartz R, Peretz T, et al. . Life and death of circulating cell-free DNA. Cancer Biol Ther 2019; 20: 1057–1067. doi:10.1080/15384047.2019.1598759 PubMed DOI PMC

Meddeb R, Dache ZAA, Thezenas S, et al. . Quantifying circulating cell-free DNA in humans. Sci Rep 2019; 9: 5220. doi:10.1038/s41598-019-41593-4 PubMed DOI PMC

Dengu F. Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation. Transplant Rev 2020; 34: 100542. doi:10.1016/j.trre.2020.100542 PubMed DOI

Sorbini M, Togliatto G, Mioli F, et al. . Validation of a simple, rapid, and cost-effective method for acute rejection monitoring in lung transplant recipients. Transpl Int 2022; 35: 10546. doi:10.3389/ti.2022.10546 PubMed DOI PMC

Oellerich M, Shipkova M, Asendorf T, et al. . Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study. Am J Transplant 2019; 19: 3087–3099. doi:10.1111/ajt.15416 PubMed DOI PMC

Tsuji N, Agbor-Enoh S. Cell-free DNA beyond a biomarker for rejection: biological trigger of tissue injury and potential therapeutics. J Heart Lung Transplant 2021; 40: 405–413. doi:10.1016/j.healun.2021.03.007 PubMed DOI

Korabecna M, Zinkova A, Brynychova I, et al. . Cell-free DNA in plasma as an essential immune system regulator. Sci Rep 2020; 10: 17478. doi:10.1038/s41598-020-74288-2 PubMed DOI PMC

Tanaka S, Sugimoto S, Kurosaki T, et al. . Donor-derived cell-free DNA is associated with acute rejection and decreased oxygenation in primary graft dysfunction after living donor-lobar lung transplantation. Sci Rep 2018; 8: 15366. doi:10.1038/s41598-018-33848-3 PubMed DOI PMC

Jang MK, Tunc I, Berry GJ, et al. . Donor-derived cell-free DNA accurately detects acute rejection in lung transplant patients, a multicenter cohort study. J Heart Lung Transplant 2021; 40: 822–830. doi:10.1016/j.healun.2021.04.009 PubMed DOI PMC

Agbor-Enoh S, Wang Y, Tunc I, et al. . Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation. EBioMedicine 2019; 40: 541–553. doi:10.1016/j.ebiom.2018.12.029 PubMed DOI PMC

Knight SR, Thorne A, Lo Faro ML. Donor-specific cell-free DNA as a biomarker in solid organ transplantation. a systematic review. Transplantation 2019; 103: 273–283. doi:10.1097/TP.0000000000002482 PubMed DOI

Keller M, Agbor-Enoh S. Cell-free DNA in lung transplantation: research tool or clinical workhorse? Curr Opin Organ Transplant 2022; 27: 177–183. doi:10.1097/MOT.0000000000000979 PubMed DOI PMC

Keller MB, Meda R, Fu S, et al. . Comparison of donor-derived cell-free DNA between single versus double lung transplant recipients. Am J Transplant 2022; 22: 2451–2457. doi:10.1111/ajt.17039 PubMed DOI PMC

Khush KK, De Vlaminck I, Luikart H, et al. . Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res 2021; 7: 00462-2020. doi:10.1183/23120541.00462-2020 PubMed DOI PMC

Keller M, Sun J, Mutebi C, et al. . Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. J Heart Lung Transplant 2022; 41: 458–466. doi:10.1016/j.healun.2021.12.009 PubMed DOI

Pedini P, Coiffard B, Cherouat N, et al. . Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation. Front Immunol 2023; 14: 1183949. doi:10.3389/fimmu.2023.1183949 PubMed DOI PMC

De Vlaminck I, Martin L, Kertesz M, et al. . Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci USA 2015; 112: 13336–13341. doi:10.1073/pnas.1517494112 PubMed DOI PMC

Rosenheck JP, Ross DJ, Botros M, et al. . Clinical validation of a plasma donor-derived cell-free DNA assay to detect allograft rejection and injury in lung transplant. Transplant Direct 2022; 8: e1317. doi:10.1097/TXD.0000000000001317 PubMed DOI PMC

Agbor-Enoh S, Jackson AM, Tunc I, et al. . Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis. J Heart Lung Transplant 2018; 37: 925–932. doi:10.1016/j.healun.2018.01.1305 PubMed DOI

Wolf-Doty TK, Mannon RB, Poggio ED, et al. . Dynamic response of donor-derived cell-free DNA following treatment of acute rejection in kidney allografts. Kidney360 2021; 2: 729–736. doi:10.34067/KID.0000042021 PubMed DOI PMC

Hinojosa RJ, Chaffin K, Gillespie M, et al. . Donor-derived cell-free DNA may confirm real-time response to treatment of acute rejection in renal transplant recipients. Transplantation 2019; 103: e61. doi:10.1097/TP.0000000000002579 PubMed DOI

Ju C, Xu X, Zhang J, et al. . Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients. BMC Pulm Med 2023; 23: 37. doi:10.1186/s12890-022-02229-y PubMed DOI PMC

Bazemore K, Permpalung N, Mathew J, et al. . Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction. Am J Transplant 2022; 22: 2560–2570. doi:10.1111/ajt.17125 PubMed DOI

Levine DJ, Demko ZP, Ross DJ. Variability in plasma donor-derived cell-free DNA levels with CLAD more than 5-years after lung transplantation: pilot data. Transplant Rep 2022; 7: 100106. doi:10.1016/j.tpr.2022.100106 DOI

Yang JYC, Verleden SE, Zarinsefat A, et al. . Cell-free DNA and CXCL10 derived from bronchoalveolar lavage predict lung transplant survival. J Clin Med 2019; 8: 241. doi:10.3390/jcm8020241 PubMed DOI PMC

Bu L, Gupta G, Pai A, et al. . Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. Kidney Int 2022; 101: 793–803. doi:10.1016/j.kint.2021.11.034 PubMed DOI

Hino S, Miyata H. Torque teno virus (TTV): current status. Rev Med Virol 2007; 17: 45–57. doi:10.1002/rmv.524 PubMed DOI

Redondo N, Navarro D, Aguado JM, et al. . Viruses, friends, and foes: the case of torque teno virus and the net state of immunosuppression. Transpl Infect Dis 2022; 24: e13778. doi:10.1111/tid.13778 PubMed DOI

Rezahosseini O, Drabe CH, Sørensen SS, et al. . Torque-teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation. Transplant Rev 2019; 33: 137–144. doi:10.1016/j.trre.2019.03.004 PubMed DOI

Görzer I, Haloschan M, Jaksch P, et al. . Plasma DNA levels of torque teno virus and immunosuppression after lung transplantation. J Heart Lung Transplant 2014; 33: 320–323. doi:10.1016/j.healun.2013.12.007 PubMed DOI

Görzer I, Jaksch P, Kundi M, et al. . Pre-transplant plasma torque teno virus load and increase dynamics after lung transplantation. PLoS One 2015; 10: e0122975. doi:10.1371/journal.pone.0122975 PubMed DOI PMC

Jaksch P, Kundi M, Görzer I, et al. . Torque teno virus as a novel biomarker targeting the efficacy of immunosuppression after lung transplantation. J Infect Dis 2018; 218: 1922–1928. doi:10.1093/infdis/jiy452 PubMed DOI

Frye BC, Bierbaum S, Falcone V, et al. . Kinetics of torque teno virus–DNA plasma load predict rejection in lung transplant recipients. Transplantation 2019; 103: 815–822. doi:10.1097/TP.0000000000002436 PubMed DOI

Nordén R, Magnusson J, Lundin A, et al. . Quantification of torque teno virus and Epstein–Barr virus is of limited value for predicting the net state of immunosuppression after lung transplantation. Open Forum Infect Dis 2018; 5: ofy050. doi:10.1093/ofid/ofy050 PubMed DOI PMC

Hoek RA, Verschuuren EA, de Vries RD, et al. . High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients. J Heart Lung Transplant 2022; 41: 765–772. doi:10.1016/j.healun.2022.03.006 PubMed DOI PMC

Gallais F, Renaud-Picard B, Solis M, et al. . Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients. J Heart Lung Transplant 2022; 41: 1429–1439. doi:10.1016/j.healun.2022.07.008 PubMed DOI PMC

Gottlieb J, Reuss A, Mayer K, et al. . Viral load-guided immunosuppression after lung transplantation (VIGILung)—study protocol for a randomized controlled trial. Trials 2021; 22: 48. doi:10.1186/s13063-020-04985-w PubMed DOI PMC

Agbor-Enoh S, Oellerich M, Wu A, et al. . Molecular approaches to transplant monitoring; is the horizon here? Clin Chem 2021; 67: 1443–1449. doi:10.1093/clinchem/hvab183 PubMed DOI

Bumgarner R. DNA microarrays: types, applications and their future. Curr Protoc Mol Biol 2013; 101: 22.1.1–22.1.11. doi:10.1002/0471142727.mb2201s101 PubMed DOI PMC

Halloran KM, Parkes MD, Chang J, et al. . Molecular assessment of rejection and injury in lung transplant biopsies. J Heart Lung Transplant 2019; 38: 504–513. doi:10.1016/j.healun.2019.01.1317 PubMed DOI

Halloran K, Parkes MD, Timofte I, et al. . Molecular T-cell-mediated rejection in transbronchial and mucosal lung transplant biopsies is associated with future risk of graft loss. J Heart Lung Transplant 2020; 39: 1327–1337. doi:10.1016/j.healun.2020.08.013 PubMed DOI

Lande J, Patil J, Li N, et al. . Novel insights into lung transplant rejection by microarray analysis. Proc Am Thorac Soc 2007; 4: 44–51. doi:10.1513/pats.200605-110JG PubMed DOI PMC

Jones NK, Conway Morris A, Curran MD, et al. . Evaluating the use of a 22-pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in intensive care. J Med Microbiol 2020; 69: 971–978. doi:10.1099/jmm.0.001218 PubMed DOI

Parkes MD, Halloran K, Hirji A, et al. . Transcripts associated with chronic lung allograft dysfunction in transbronchial biopsies of lung transplants. Am J Transplant 2022; 22: 1054–1072. doi:10.1111/ajt.16895 PubMed DOI

Halloran K, Mackova M, Parkes MD, et al. . The molecular features of chronic lung allograft dysfunction in lung transplant airway mucosa. J Heart Lung Transplant 2022; 41: 1689–1699. doi:10.1016/j.healun.2022.08.014 PubMed DOI

Jaksik R, Iwanaszko M, Rzeszowska-Wolny J, et al. . Microarray experiments and factors which affect their reliability. Biol Direct 2015; 10: 46. doi:10.1186/s13062-015-0077-2 PubMed DOI PMC

Randhawa PS. The molecular microscope diagnostic system (MMDx) in transplantation: a pathologist's perspective. Am J Transplant 2020; 20: 1965–1966. doi:10.1111/ajt.15887 PubMed DOI

Halloran PF, Reeve J, Madill-Thomsen KS, et al. . The trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol 2022; 33: 387–400. doi:10.1681/ASN.2021091191 PubMed DOI PMC

Park S, Guo K, Heilman RL, et al. . Combining blood gene expression and cellfree DNA to diagnose subclinical rejection in kidney transplant recipients. Clin J Am Soc Nephrol 2021; 16: 1539–1551. doi:10.2215/CJN.05530421 PubMed DOI PMC

Wang Y, Wang J-Y, Schnieke A, et al. . Advances in single-cell sequencing: insights from organ transplantation. Mil Med Res 2021; 8: 45. doi:10.1186/s40779-021-00336-1 PubMed DOI PMC

Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol 2019; 20: 21–37. doi:10.1038/s41580-018-0045-7 PubMed DOI PMC

Hoefel G, Tay H, Foster P. MicroRNAs in lung diseases. Chest 2019; 156: 991–1000. doi:10.1016/j.chest.2019.06.008 PubMed DOI

Palleschi A, Gaudioso G, Edefonti V, et al. . Bronchoalveolar lavage-microRNAs are potential novel biomarkers of outcome after lung transplantation. Transplant Direct 2020; 6: e547. doi:10.1097/TXD.0000000000000994 PubMed DOI PMC

Ouyang T, Liu Z, Han Z, et al. . MicroRNA detection specificity: recent advances and future perspective. Anal Chem 2019; 91: 3179–3186. doi:10.1021/acs.analchem.8b05909 PubMed DOI

Zhang W, Zhou T, Ma S-F, et al. . MicroRNAs implicated in dysregulation of gene expression following human lung transplantation. Transl Respir Med 2013; 1: 12. doi:10.1186/2213-0802-1-12 PubMed DOI PMC

Ladak SS, Ward C, Ali S. The potential role of microRNAs in lung allograft rejection. J Heart Lung Transplant 2016; 35: 550–559. doi:10.1016/j.healun.2016.03.018 PubMed DOI

Budding K, Rossato M, van de Graaf EA, et al. . Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation. Transpl Immunol 2017; 42: 1–4. doi:10.1016/j.trim.2017.04.002 PubMed DOI

Shiotani T, Sugimoto S, Tomioka Y, et al. . Diagnostic value of circulating microRNA-21 in chronic lung allograft dysfunction after bilateral cadaveric and living-donor lobar lung transplantation. Heliyon 2023; 9: e14903. doi:10.1016/j.heliyon.2023.e14903 PubMed DOI PMC

Bozzini S, Pandolfi L, Rossi E, et al. . MiRNAs potentially involved in post lung transplant-obliterative bronchiolitis: the role of miRNA-21-5p. Cells 2021; 10: 688. doi:10.3390/cells10030688 PubMed DOI PMC

Bozzini S, Del Fante C, Morosini M, et al. . Mechanisms of action of extracorporeal photopheresis in the control of bronchiolitis obliterans syndrome (BOS): involvement of circulating miRNAs. Cells 2022; 11: 1117. doi:10.3390/cells11071117 PubMed DOI PMC

Benazzo A, Bozzini S, Auner S, et al. . Differential expression of circulating miRNAs after alemtuzumab induction therapy in lung transplantation. Sci Rep 2022; 12: 7072. doi:10.1038/s41598-022-10866-w PubMed DOI PMC

de Gonzalo-Calvo D, Pérez-Boza J, Curado J, et al. . Challenges of microRNA-based biomarkers in clinical application for cardiovascular diseases. Clin Transl Med 2022; 12: e585. doi:10.1002/ctm2.585 PubMed DOI PMC

Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet 2019; 10: 478. doi:10.3389/fgene.2019.00478 PubMed DOI PMC

Wagner W. How to translate DNA methylation biomarkers into clinical practice. Front Cell Dev Biol 2022; 10: 854797. doi:10.3389/fcell.2022.854797 PubMed DOI PMC

Bell CG, Lowe R, Adams PD, et al. . DNA methylation aging clocks: challenges and recommendations. Genome Biol 2019; 20: 249. doi:10.1186/s13059-019-1824-y PubMed DOI PMC

Legaki E, Arsenis C, Taka S, et al. . DNA methylation biomarkers in asthma and rhinitis: are we there yet? Clin Transl Allergy 2022; 12: e12131. doi:10.1002/clt2.12131 PubMed DOI PMC

Benincasa G, DeMeo DL, Glass K, et al. . Epigenetics and pulmonary diseases in the horizon of precision medicine: a review. Eur Respir J 2021; 57: 2003406. doi:10.1183/13993003.03406-2020 PubMed DOI

Dugger DT, Calabrese DR, Gao Y, et al. . Lung allograft epithelium DNA methylation age is associated with graft chronologic age and primary graft dysfunction. Front Immunol 2021; 12: 704172. doi:10.3389/fimmu.2021.704172 PubMed DOI PMC

Jang M, Singh K, Andargie T, et al. . Genome-wide DNA methylation analysis to define pulmonary antibody-mediated rejection (AMR) treatment response. J Heart Lung Transplant 2022; 41: S39. doi:10.1016/j.healun.2022.01.088 DOI

Agbor-Enoh S, Seifuddin F, Pirooznia M, et al. . Pulmonary antibody-mediated rejection (AMR) accelerates aging-evidence from whole genome DNA methylation sequencing. J Heart Lung Transplant 2019; 38: Suppl., S138. doi:10.1016/j.healun.2019.01.328 DOI

Cristoferi I, Giacon TA, Boer K, et al. . The applications of DNA methylation as a biomarker in kidney transplantation: a systematic review. Clin Epigenetics 2022; 14: 20. doi:10.1186/s13148-022-01241-7 PubMed DOI PMC

Peters FS, Manintveld OC, Betjes MGH, et al. . Clinical potential of DNA methylation in organ transplantation. J Heart Lung Transplant 2016; 35: 843–850. doi:10.1016/j.healun.2016.02.007 PubMed DOI

Vasco M, Benincasa G, Fiorito C, et al. . Clinical epigenetics and acute/chronic rejection in solid organ transplantation: an update. Transplant Rev 2021; 35: 100609. doi:10.1016/j.trre.2021.100609 PubMed DOI

Edgar JR. Q&A: What are exosomes, exactly? BMC Biol 2016; 14: 46. doi:10.1186/s12915-016-0268-z PubMed DOI PMC

Wang N, Wang Q, Du T, et al. . The potential roles of exosomes in chronic obstructive pulmonary disease. Front Med 2021; 7: 618506. doi:10.3389/fmed.2020.618506 PubMed DOI PMC

Yang Y, Liu Y, Chai Y, et al. . Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis. Front Pharmacol 2022; 13: 927653. doi:10.3389/fphar.2022.927653 PubMed DOI PMC

King's College London . Improving the early detection of lung cancer by combining exosomal analysis of hypoxia with standard of care imaging (LungExoDETECT) Date last accessed: 17 June 2022. Date last updated: 16 November 2020. https://clinicaltrials.gov/study/NCT04629079

Weiss M. Immune modulation by stem cell derived exosomes in critically ill COVID-19. Date last accessed: 17 June 2022. Date last updated: 2 February 2022. https://clinicaltrials.gov/study/NCT05191381

Ludwig N, Whiteside TL, Reichert TE. Challenges in exosome isolation and analysis in health and disease. Int J Mol Sci 2019; 20: 4684. doi:10.3390/ijms20194684 PubMed DOI PMC

Gunasekaran M, Xu Z, Nayak DK, et al. . Donor-derived exosomes with lung self-antigens in human lung allograft rejection. Am J Transplant 2017; 17: 474–484. doi:10.1111/ajt.13915 PubMed DOI PMC

Zaffiri L, Shah RJ, Stearman RS, et al. . Collagen type-V is a danger signal associated with primary graft dysfunction in lung transplantation. Transpl Immunol 2019; 56: 101224. doi:10.1016/j.trim.2019.101224 PubMed DOI

Tiriveedhi V, Gautam B, Sarma NJ, et al. . Pre-transplant antibodies to kα1 tubulin and collagen-v in lung transplantation: clinical correlations. J Heart Lung Transplant 2013; 32: 807–814. doi:10.1016/j.healun.2013.06.003 PubMed DOI PMC

Habertheuer A, Ram C, Schmierer M, et al. . Circulating donor lung-specific exosome profiles enable noninvasive monitoring of acute rejection in a rodent orthotopic lung transplantation model. Transplantation 2022; 106: 754–766. doi:10.1097/TP.0000000000003820 PubMed DOI

Gunasekaran M, Bansal S, Ravichandran R, et al. . Respiratory viral infection in lung transplantation induces exosomes that trigger chronic rejection. J Heart Lung Transplant 2020; 39: 379–388. doi:10.1016/j.healun.2019.12.009 PubMed DOI PMC

Bansal S, Fleming T, Perincheri S, et al. . Lung transplant recipients with SARS-CoV-2 infection induce circulating exosomes with SARS-CoV-2 spike protein S2 which are immunogenic in mice. J Heart Lung Transplant 2022; 41: S134. doi:10.1016/j.healun.2022.01.314 DOI

Sharma M, Gunasekaran M, Ravichandran R, et al. . Circulating exosomes with lung self-antigens as a biomarker for chronic lung allograft dysfunction: a retrospective analysis. J Heart Lung Transplant 2020; 39: 1210–1219. doi:10.1016/j.healun.2020.07.001 PubMed DOI PMC

Ravichandran R, Bansal S, Rahman M, et al. . The role of donor-derived exosomes in lung allograft rejection. Hum Immunol 2019; 80: 588–594. doi:10.1016/j.humimm.2019.03.012 PubMed DOI PMC

Hsin MKY, Liu M. Commentary: it's time for exosomes to get the limelight in lung transplant. J Thorac Cardiovasc Surg 2021; 161: e136–e137. doi:10.1016/j.jtcvs.2020.04.155 PubMed DOI

Mazzatenta A, Pokorski M, Sartucci F, et al. . Volatile organic compounds (VOCs) fingerprint of Alzheimer's disease. Respir Physiol Neurobiol 2015; 209: 81–84. doi:10.1016/j.resp.2014.10.001 PubMed DOI

Mazzatenta A, Pokorski M, Di Giulio C. Volatile organic compounds (VOCs) in exhaled breath as a marker of hypoxia in multiple chemical sensitivity. Physiol Rep 2021; 9: e15034. doi:10.14814/phy2.15034 PubMed DOI PMC

Wijbenga N, Hoek RAS, Mathot BJ, et al. . The potential of electronic nose technology in lung transplantation: a proof of principle. ERJ Open Res 2022; 8: 00048-2022. doi:10.1183/23120541.00048-2022 PubMed DOI PMC

Rai SN, Das S, Pan J, et al. . Multigroup prediction in lung cancer patients and comparative controls using signature of volatile organic compounds in breath samples. PloS One 2022; 17: e0277431. doi:10.1371/journal.pone.0277431 PubMed DOI PMC

Binson VA, Subramoniam M, Mathew L. Detection of COPD and lung cancer with electronic nose using ensemble learning methods. Clin Chim Acta 2021; 523: 231–238. doi:10.1016/j.cca.2021.10.005 PubMed DOI

Zang X, Monge ME, Gaul DA, et al. . Early detection of cystic fibrosis acute pulmonary exacerbations by exhaled breath condensate metabolomics. J Proteome Res 2020; 19: 144–152. doi:10.1021/acs.jproteome.9b00443 PubMed DOI

Verleden SE, Hendriks JMH, Lauwers P, et al. . Biomarkers for chronic lung allograft dysfunction: ready for prime time? Transplantation 2023; 107: 341–350. doi:10.1097/TP.0000000000004270 PubMed DOI PMC

Brosseau C, Danger R, Durand M, et al. . Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2019; 19: 3162–3175. doi:10.1111/ajt.15532 PubMed DOI

Smirnova NF, Riemondy K, Bueno M, et al. . Single-cell transcriptome mapping identifies a local, innate B cell population driving chronic rejection after lung transplantation. JCI Insight 2022; 7: e156648. doi:10.1172/jci.insight.156648 PubMed DOI PMC

Durand M, Lacoste P, Danger R, et al. . High circulating CD4+CD25hiFOXP3+ T-cell sub-population early after lung transplantation is associated with development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2018; 37: 770–781. doi:10.1016/j.healun.2018.01.1306 PubMed DOI

Ius F, Salman J, Knoefel A-K, et al. . Increased frequency of CD4+ CD25high CD127low T cells early after lung transplant is associated with improved graft survival – a retrospective study. Transpl Int 2020; 33: 503–516. doi:10.1111/tri.13568 PubMed DOI

Brugière O, Mouren D, Trichereau J, et al. . Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G. J Heart Lung Transplant 2022; 41: 626–640. doi:10.1016/j.healun.2022.01.013 PubMed DOI

Newton CA, Kozlitina J, Lines JR, et al. . Telomere length in patients with pulmonary fibrosis associated with chronic lung allograft dysfunction and post-lung transplantation survival. J Heart Lung Transplant 2017; 36: 845–853. doi:10.1016/j.healun.2017.02.005 PubMed DOI PMC

Courtwright AM, Lamattina AM, Takahashi M, et al. . Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Res 2020; 6: 00003-2020. doi:10.1183/23120541.00003-2020 PubMed DOI PMC

Courtwright AM, Fried S, Villalba JA, et al. . Association of donor and recipient telomere length with clinical outcomes following lung transplantation. PLoS One 2016; 11: e0162409. doi:10.1371/journal.pone.0162409 PubMed DOI PMC

Newton CA, Zhang D, Oldham JM, et al. . Telomere length and use of immunosuppressive medications in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2019; 200: 336–347. doi:10.1164/rccm.201809-1646OC PubMed DOI PMC

Treatment Responses in Histologic Versus Molecular Diagnoses of Lung Rejection